FrancophonIA/ELRC3.0 huggingface dataset:
English: The medicine contains the active substances aliskiren and hydrochlorothiazide.
Estonian: Ravim sisaldab toimeainena aliskireeni ja hüdroklorotiasiidi.
English: Rasilez HCT is used in patients whose blood pressure is not adequately controlled by aliskiren or hydrochlorothiazide taken alone.
Estonian: Ravimit Rasilez HCT kasutatakse patsientidel, kelle vererõhk ei allu üksnes aliskireeni või hüdroklorotiasiidiga piisavalt ravile.
English: Rasilez HCT must not be used in patients who have had angioedema (swelling under the skin) with aliskiren, hereditary angioedema or angioedema of no obvious cause, who have anuria (a condition in which a patient cannot make or pass urine), severe kidney or liver impairment, or whose blood potassium levels are too low or blood calcium levels are too high.
Estonian: Ravimit Rasilez HCT ei tohi kasutada patsiendid, kellel on olnud aliskireeni kasutamisel angioödeem (nahaalune turse), pärilik või teadmata põhjusega angioödeem, kellel on anuuria (kuseerituse puudumine), raske neeru- või maksakahjustus või kelle vere kaaliumisisaldus on liiga väike või kaltsiumisisaldus liiga suur.
English: Other information about Rasilez HCT
Estonian: Muu teave ravimi Rasilez HCT kohta
English: In patients whose blood pressure was not adequately controlled on either aliskiren or hydrochlorothiazide alone, switching to the combination resulted in greater falls in blood pressure than remaining on one active substance alone.
Estonian: Patsientidel, kelle vererõhk ei allunud piisavalt ravile üksnes aliskireeni või hüdroklorotiasiidiga, vähenes toimeainete kombinatsioonile ülemineku tulemusena vererõhk rohkem kui ravi jätkamisel ainult ühe toimeainega.
English: The two active substances in Rasilez HCT, aliskiren and hydrochlorothiazide, work in different ways to reduce blood pressure.
Estonian: Ravimi Rasilez HCT kaks toimeainet aliskireen ja hüdroklorotiasiid alandavad vererõhku eri viisidel.
English: Results showed that Rasilez HCT was more effective than placebo in reducing blood pressure.
Estonian: Tulemuste kohaselt vähendas Rasilez HCT vererõhku efektiivsemalt kui platseebo.
English: Taking the two active substances in one tablet is expected to help patients to stick to their treatment.
Estonian: Eeldatavalt aitab kahe toimeaine manustamine ühe tabletina patsientidel järgida raviskeemi.
English: By lowering blood pressure, the risk caused by high blood pressure, such as having a stroke, is reduced.
Estonian: Vererõhu langusega väheneb kõrgest vererõhust tingitud seisundite, näiteks insuldi risk.
English: The medicine has been shown to reduce blood pressure more than each active substance alone.
Estonian: Tõendite kohaselt alandab ravim vererõhku rohkem kui kumbki toimeaine eraldi.
English: It can also be used in patients whose blood pressure is adequately controlled with aliskiren and hydrochlorothiazide taken as separate tablets, to replace the same doses of the two active substances.
Estonian: Ravimit tohivad kasutada ka patsiendid, kelle vererõhk allub piisavalt ravile aliskireeni ja hüdroklorotiasiidi eraldi võetavate tablettidega, et asendada kaks tabletti ühega, mis sisaldab kaht toimeainet samas annuses.
English: For the full list of all side effects reported with Rasilez HCT, see the package leaflet.
Estonian: Ravimi Rasilez HCT kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: How does Rasilez HCT work?
Estonian: Kuidas Rasilez HCT toimib?
English: It must not be taken with ciclosporin, itraconazole or other medicines known as ‘potent P-glycoprotein inhibitors' (such as quinidine).
Estonian: Ravimit Rasilez HCT ei tohi võtta koos tsüklosporiini, itrakonasooli ega teiste tugevate P-glükoproteiini inhibiitoritega (nt kinidiin).
English: What are the risks associated with Rasilez HCT?
Estonian: Mis riskid ravimiga Rasilez HCT kaasnevad?
English: An overview of Rasilez HCT and why it is authorised in the EU
Estonian: Ülevaade ravimist Rasilez HCT ja ELis müügiloa väljastamise põhjendus
English: In patients already adequately controlled with the two active substances, the dose of Rasilez HCT must contain the same doses of aliskiren and hydrochlorothiazide that the patient was taking before.
Estonian: Kui patsiendi vererõhk allub mõlemale toimeainele piisavalt, peab Rasilez HCT sisaldama aliskireeni ja hüdroklorotiasiidi annuses, mida patsient võttis varem.
English: How is Rasilez HCT used?
Estonian: Kuidas ravimit Rasilez HCT kasutatakse?
English: After two to four weeks of taking Rasilez HCT, the dose can be increased in patients whose blood pressure remains uncontrolled.
Estonian: Kui patsiendi vererõhk ei allu ravimiga Rasilez HCT toimuvale ravile, tohib pärast 2-4-nädalast ravi annust suurendada.
English: Rasilez HCT in combination with an ‘angiotensin converting enzyme (ACE) inhibitors' or ‘angiotensin receptor blockers' (ARBs) must not be used in patients with diabetes,
Estonian: Diabeedi või mõõduka või raske neerukahjustusega patsiendid ei tohi ravimit Rasilez HCT kasutada koos angiotensiini muundava ensüümi (ACE) inhibiitorite ega angiotensiini retseptori blokaatoritega (ARB).
English: What benefits of Rasilez HCT have been shown in studies?
Estonian: Milles seisneb uuringute põhjal ravimi Rasilez HCT kasulikkus?
English: The dose depends on the doses of aliskiren or hydrochlorothiazide that the patient was taking before.
Estonian: Annus sõltub patsiendi varasemast aliskireeni või hüdroklorotiasiidi annusest.
English: It has also been shown to have a beneficial impact on the quality of life of patients.
Estonian: Samuti on tuvastatud soodne mõju patsientide elukvaliteedile.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Constella on 26 November 2012.
Estonian: Euroopa Komisjon andis Constella müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 26. novembril 2012.
English: It is available as capsules (290 micrograms).
Estonian: Seda turustatakse kapslitena (290 µg).
English: The full EPAR for Constella can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Constella kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: This summary was last updated in November 2012.
Estonian: Kokkuvõtte viimane uuendus: november 2012
English: Other information about Constella
Estonian: Muu teave Constella kohta
English: The recommended dose of Constella is one capsule once a day, taken at least 30 minutes before a meal.
Estonian: Constella soovitatav annus on üks kapsel üks kord ööpäevas, mis tuleb võtta vähemalt 30 minutit enne sööki.
English: The doctor should periodically assess the need of continued treatment.
Estonian: Arst peab perioodiliselt hindama jätkuva Constellaga ravimise vajadust.
English: If the patient has not experienced an improvement in symptoms after four weeks of treatment, the benefits and risks of continuing treatment should be reconsidered.
Estonian: Kui patsiendi sümptomid ei ole pärast neljanädalast ravi leevenenud, siis tuleb ravi jätkamisest saadavat kasu ja riske uuesti kaaluda.
English: However, the Committee also noted that about half of the patients did not adequately benefit from treatment, and therefore recommended that the need for continued treatment should be reconsidered after four weeks.
Estonian: Siiski märkis inimravimite komitee, et umbes pooled patsientidest ei saanud ravist piisavat kasu, ja soovitas seetõttu, et ravi jätkamise vajadust tuleb taashinnata pärast neljanädalast ravi.
English: One of the studies also looked at the effects of Constella following 26 weeks of treatment.
Estonian: Ühes uuringus hinnati Constella toimet ka 26nädalase ravi jooksul.
English: Constella is a medicine that contains the active substance linaclotide.
Estonian: Constella on ravim, mis sisaldab toimeainena linaklotiidi.
English: Why has Constella been approved?
Estonian: Miks Constella heaks kiideti?
English: In rare and more severe cases, diarrhoea may lead to dehydration, hypokalaemia (low blood potassium levels), decrease in blood bicarbonate, dizziness and orthostatic hypotension (low blood pressure on standing up).
Estonian: Harvadel ja raskematel juhtudel võib kõhulahtisus põhjustada dehüdratsiooni, hüpokaleemiat (vere väike kaaliumisisaldus), vere bikarbonaatide sisalduse vähenemist, uimasust ja ortostaatilist hüpotensiooni (madal vererõhk lamavast asendist püsti tõustes).
English: The CHMP therefore decided that Constella's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Seetõttu otsustas inimravimite komitee, et Constella kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: For more information about treatment with Constella, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Constellaga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: This is a summary of the European public assessment report (EPAR) for Constella.
Estonian: See on ravimi Constella Euroopa avaliku hindamisaruande kokkuvõte.
English: The most common side effect with Constella is diarrhoea, mainly mild to moderate, occurring in between 10 and 20 patients in 100.
Estonian: Constella kõige sagedam kõrvalnäht on kõhulahtisus, mis enamasti on kerge kuni mõõdukas ja esineb 10-20 patsiendil 100st.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Constella.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: Constella was investigated in two main studies involving a total of 1,608 patients with IBS with constipation, where it was compared with placebo (a dummy treatment).
Estonian: Constellat uuriti kahes põhiuuringus, milles osales kokku 1608 ärritatud soole sündroomi ja kõhukinnisusega patsienti ning mille käigus võrreldi Constellat platseeboga (näiv ravim).
English: What is Constella?
Estonian: Mis on Constella?
English: It must also not be used in patients with a known or suspected blockage in their stomach or gut.
Estonian: Samuti ei tohi seda kasutada patsiendid, kellel on mao või soole obstruktsioon või kellel seda kahtlustatakse.
English: Constella must not be used in people who are hypersensitive (allergic) to linaclotide or any of the other ingredients.
Estonian: Constellat ei tohi kasutada patsiendid, kes on linaklotiidi või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: Regarding safety, the CHMP concluded that the side effects with Constella, mainly diarrhoea, are manageable.
Estonian: Ohutuse osas järeldas inimravimite komitee, et Constella kõrvalnähte, eelkõige kõhulahtisust, saab hoida kontrolli all.
English: What is the risk associated with Constella?
Estonian: Mis riskid Constellaga kaasnevad?
English: The CHMP noted that Constella has been shown to have clinically relevant, beneficial effects in patients with IBS with constipation in the long term (for up to six months).
Estonian: Inimravimite komitee märkis, et Constella puhul on ärritatud soole sündroomiga patsientidel täheldatud pikaajalist (kestusega kuni 6 kuud) kliiniliselt olulist kasulikku toimet.
English: The effects of Constella were first tested in experimental models before being studied in humans.
Estonian: Enne inimuuringuid kontrolliti Constella toimet muude katsetega.
English: What benefit has Constella shown during the studies?
Estonian: Milles seisneb uuringute põhjal Constella kasulikkus?
English: IBS is a long-term disorder of the gut characterised by pain or discomfort in the abdomen and bloating together with altered bowel habit.
Estonian: Ärritatud soole sündroom on pikaajaline soolehaigus, mida iseloomustavad valu või ebamugavustunne kõhus koos sooletegevuse muutustega.
English: Constella is used to treat the symptoms of moderate to severe irritable bowel syndrome (IBS) with constipation in adults.
Estonian: Constellat kasutatakse täiskasvanute raviks, kellel esinevad mõõduka kuni raske ärritatud soole sündroomi sümptomid koos kõhukinnisusega.
English: The results after 26 weeks of treatment showed an improvement in pain (for at least 13 weeks out of the 26 weeks) in 54% of patients taking Constella compared with 36% of patients taking placebo, as well as relief from symptoms for at least 13 weeks in 37% of Constella patients, compared with 17% of patients in the placebo group.
Estonian: 26nädalase ravi järel täheldati valu vähenemist (vähemalt 13 nädalal 26 ravinädalast) 54%-l Constellat võtnud patsientidest võrreldes 36%-ga platseebot võtnud patsientidest ning sümptomite leevenemist vähemalt 13 nädalal 26 ravinädalast 37%-l Constellat võtnud patsientidest võrreldes 17%-ga platseeborühma patsientidest.
English: EPAR summary for the public linaclotide
Estonian: Kokkuvõte üldsusele
English: The main measures of effectiveness were the number of patients who experienced at least a 30% improvement in their pain and discomfort and the number of patients who were considerably or completely relieved from all IBS symptoms for at least 6 out of the 12 weeks of treatment.
Estonian: Uuringutes oli efektiivsuse põhinäitaja patsientide arv, kellel täheldati valu ja ebamugavustunde vähemalt 30% vähenemist, samuti patsientide arv, kellel leevenesid oluliselt või kadusid täielikult kõik ärritatud soole sündroomi sümptomid vähemalt 6 nädalal 12 ravinädalast.
English: Similar results were obtained in the second study, with 54% of Constella patients experiencing an improvement in their pain and discomfort and 39% of them feeling considerably or completely relieved from symptoms for at least 6 out of the 12 weeks of treatment, compared with 39% and 17% of patients in the placebo group, respectively.
Estonian: Sarnaseid tulemusi täheldati ka teises uuringus, milles 54%-l Constellat saanud patsientidest täheldati valu ja ebamugavustunde vähenemist ning 39%-l patsientidest vähenesid sümptomid oluliselt või kadusid täiesti vähemalt 6 nädalal 12 ravinädalast võrreldes vastavalt 39%-ga ja 17%-ga platseeborühma patsientidest.
English: Constella was shown to be more effective than placebo at improving the symptoms of IBS.
Estonian: Constella oli ärritatud soole sündroomi sümptomite leevendamisel tõhusam kui platseebo.
English: In the first study, 55% of patients who received Constella experienced a 30% or higher improvement in their pain and discomfort for at least 6 out of the 12 weeks of treatment, compared with 42% of patients who received placebo.
Estonian: Esimeses uuringus täheldati 55%-l Constellat saanud patsientidest vähemalt 6 nädalal 12 ravinädalast 30% või suuremat valu ja ebamugavustunde vähenemist võrreldes 42%-ga platseebot saanud patsientidest.
English: How is Constella used?
Estonian: Kuidas Constellat kasutatakse?
English: In addition, 37% of patients who received Constella were considerably or completely relieved from symptoms for at least 6 out of the 12 weeks of treatment, compared with 19% of patients who received placebo.
Estonian: Peale selle vähenesid 37%-l Constellat saanud patsientidest vähemalt 6 nädalal 12 ravinädalast sümptomid oluliselt või kadusid täielikult võrreldes 19%-ga platseebot saanud patsientidest.
English: The active substance in Constella, linaclotide, attaches to some receptors in the gut called guanylate cyclase C. By attaching to these receptors, it reduces pain and increases the secretion of fluid into the gut, thereby loosening the stools and increasing bowel movements.
Estonian: Nende retseptoritega seondudes vähendab linaklotiid valu ja suurendab vedeliku sekretsiooni soolde, mis pehmendab väljaheite konsistentsi ja intensiivistab soolemotoorikat.
English: The medicine can only be obtained with a prescription.
Estonian: Constella on retseptiravim.
English: How does Constella work?
Estonian: Kuidas Constella toimib?
English: How has Constella been studied?
Estonian: Kuidas Constellat uuriti?
English: What is Constella used for?
Estonian: Milleks Constellat kasutatakse?
English: Melosus received a marketing authorisation valid throughout the EU on21 February 2011.
Estonian: Melosusi müügiluba, mis kehtib kogu Euroopa Liidus, anti 21. veebruaril 2011.
English: What is Melosus and what is it used for?
Estonian: Mis on Melosus ja milleks seda kasutatakse?
English: Further information on Melosus can be found on the Agency's website: ema.europa.eu/medicines/veterinary/EPAR/melosus.
Estonian: Lisateave Melosusi kohta on ameti veebilehel: ema.europa.eu/medicines/veterinary/EPAR/melosus.
English: Other information about Melosus
Estonian: Muu teave Melosusi kohta
English: As for every medicine, the company provided studies on the quality of Melosus.
Estonian: Nagu iga ravimi korral, esitas ettevõte Melosusi kvaliteedi uuringud.
English: The company also carried out studies that showed that it is ‘bioequivalent' to the reference medicine.
Estonian: Ettevõte tegi ka uuringuid, mis näitasid, et see on bioekvivalentne võrdlusravimiga.
English: The European Medicines Agency concluded that, in accordance with EU requirements, Melosus has been shown to have comparable quality and to be bioequivalent to Metacam.
Estonian: Euroopa Ravimiamet järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud ravimi Melosus võrreldav kvaliteet ja bioekvivalentsus Metacamiga.
English: As prostaglandins trigger inflammation, pain, exudation (fluid that leaks out of blood vessels during an inflammation) and fever, meloxicam reduces these signs of inflammation.
Estonian: Et prostaglandiinid tekitavad põletikku, valu, eksudatsiooni (põletiku korral veresoontest väljaimbuv vedelik) ja palavikku, vähendab meloksikaam neid põletiku sümptomeid.
English: Melosus (meloxicam)1
Estonian: Melosus (meloksikaam)
English: Studies on the benefits and risks of the active substance in the authorised uses have already been carried out with the reference medicine, Metacam, and do not need to be repeated for Melosus.
Estonian: Võrdlusravimiga Metacam on juba tehtud toimeaine heakskiidetud kasutamisviiside kasulikkuse ja riski uuringud ja neid ei ole vaja Melosusiga korrata.
English: An overview of Melosus and why it is authorised in the EU
Estonian: Melosusi ülevaade ja Euroopa Liidus heakskiitmise põhjused
English: Melosus is available as an oral (taken by mouth) suspension as 0.5 mg/ml for use in cats and guinea pigs and 1.5 mg/ml for use in dogs.
Estonian: Melosusi turustatakse suukaudse suspensioonina kontsentratsiooniga 0,5 mg/ml kassidel ja merisigadel kasutamiseks ning kontsentratsiooniga 1,5 mg/ml koertel kasutamiseks.
English: Therefore, the Agency's view was that, as for Metacam, the benefit of Melosus outweighs the identified risk and it can be authorised for use in the EU.
Estonian: Seetõttu on amet arvamusel, et nagu ka Metacami korral, ületab Melosusi kasulikkus sellega kaasnevad riskid ja ravimi kasutamise võib Euroopa Liidus heaks kiita.
English: This means that Melosus contains the same active substance and works in the same way as a ‘reference medicine' already authorised in the European Union (EU) called Metacam.
Estonian: See tähendab, et Melosus sisaldab sama toimeainet ja toimib samal viisil kui võrdlusravim Metacam, millel juba on Euroopa Liidus müügiluba.
English: Because Melosus is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Estonian: Et Melosus on geneeriline ravim ja võrdlusravimiga bioekvivalentne, peetakse tema kasulikkust ja riske samaks mis võrdlusravimil.
English: The dose depends on the animal, the bodyweight and condition and is given mixed with food or directly into the mouth for dogs and cats and directly into the mouth for guinea pigs.
Estonian: Annus sõltub looma liigist, kehamassist ja seisundist ning seda manustatakse koertele ja kassidele toiduga segatuna või otse suhu ning merisigadele otse suhu.
English: Previously known as Melocam.
Estonian: Varasem nimetus Melocam.
English: For further information about using Melosus, see the package leaflet or contact your veterinarian or pharmacist.
Estonian: Kui vajate Melosusiga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte või pöörduge oma veterinaararsti või apteekri poole.
English: Melosus contains meloxicam, which belongs to a class of medicines called non-steroidal antiinflammatory drugs (NSAIDs).
Estonian: Melosus sisaldab meloksikaami, mis kuulub mittesteroidsete põletikuvastaste ravimite (NSAID) klassi.
English: Safety information has been included in the summary of product characteristics and the package leaflet for Melosus, including the appropriate precautions to be followed by healthcare professionals and animal owners or keepers.
Estonian: Ravimi omaduste kokkuvõttesse ja pakendi infolehele lisati Melosusi ohutusteave, kus on ka tervishoiuspetsialistide ja loomaomanike või -pidajate võetavad meetmed.
English: Melosus is an anti-inflammatory medicine used in dogs, cats and guinea pigs.
Estonian: Melosus on põletikuvastane ravim, mida kasutatakse koertel, kassidel ja merisigadel.
English: How does Melosus work?
Estonian: Kuidas Melosus toimib?
English: Melosus contains the active substance meloxicam and is a ‘generic medicine'.
Estonian: Melosus sisaldab toimeainena meloksikaami ja on geneeriline ravim.
English: What are the benefits and risks of Melosus?
Estonian: Milles seisneb Melosusi kasulikkus ja mis riskid ravimiga kaasnevad?
English: How is Melosus used?
Estonian: Kuidas Melosusi kasutatakse?
English: In cats, Melosus is used to reduce pain and inflammation after orthopaedic and minor soft tissue surgery.
Estonian: Kassidel kasutatakse Melosusi valu ja põletiku vähendamiseks pärast ortopeedilisi ja väikesi pehmete kudede operatsioone.
English: How has Melosus been studied?
Estonian: Kuidas Melosusi uuriti?
English: In guinea pigs Melosus is used to reduce pain after soft tissue surgery such as castration.
Estonian: Merisigadel kasutatakse Melosusi valu vähendamiseks pärast pehmete kudede operatsioone, näiteks pärast kastreerimist.
English: In dogs, Melosus is used to lessen inflammation and pain in musculo-skeletal disorders.
Estonian: Koertel kasutatakse Melosusi põletiku ja valu leevendamiseks luu- ja lihaskonna vaevuste korral.
English: Moreover, it is used to lessen pain and inflammation in chronic musculo-skeletal disorders.
Estonian: Melosusi kasutatakse ka valu ja põletiku leevendamiseks krooniliste luu- ja lihaskonna vaevuste korral.
English: Melosus can only be obtained with a prescription.
Estonian: Melosus on retseptiravim.
English: Why is Melosus authorised in the EU?
Estonian: Melosusi Euroopa Liidus heakskiitmise põhjused
English: • hypertension;
Estonian: • hüpertensioon;
English: What is Plendil?
Estonian: Mis on Plendil?
English: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Spain, Sweden and United Kingdom, as well as in Iceland and Norway.
Estonian: Plendilit ja sarnaseid nimetusi turustatakse praegu järgmistes Euroopa Liidu liikmesriikides: Austrias, Belgias, Bulgaarias, Eestis, Hispaanias, Horvaatias, Iirimaal, Itaalias, Kreekas, Küprosel, Leedus, Luksemburgis, Lätis, Madalmaades, Maltas, Poolas, Portugalis, Prantsusmaal, Rootsis, Rumeenias, Saksamaal, Slovakkias, Soomes, Taanis, Tšehhi Vabariigis, Ungaris ja Ühendkuningriigis ning ka Islandil ja Norras.
English: Why was Plendil reviewed?
Estonian: Miks Plendili taotlus uuesti läbi vaadati?
English: The company that markets these medicines is AstraZeneca.
Estonian: Neid ravimeid turustav ettevõte on AstraZeneca.
English: Plendil and associated names have been authorised in EU Member States through national procedures since 1987.
Estonian: Plendil ja sarnased nimetused on olnud Euroopa Liidu liikmesriikides riiklike menetluste kaudu heaks kiidetud aastast 1987.